MEDICAL

TeselaGen Biotechnology Announced the Launch of a New Protein Optimization Toolkit for Automated Biotherapeutic Drug Design and Development

TeselaGen Biotechnology | May 21, 2021

TeselaGen Biotechnology today announced the launch of a new protein optimization toolkit for biotherapeutic drug design and development, introducing significant enhancements to the company’s flagship TeselaGen® OS to form designing and developing pharmaceuticals and biotherapeutics faster and fewer expensive. The new capabilities, easily accessible via the cloud-based platform, simplify the planning of highly complex combinatorial protein libraries and support AI models for optimizing new peptides and proteins. New application programming interfaces (APIs) and integration tools have also been extended to further enhance users’ access to the new capabilities.

TeselaGen integrates the facility of AI with one end-to-end platform for design, construction, data gathering, and analysis of bioproduct performance, from pharmaceuticals to food and fabrics, significantly accelerating time to plug and reducing costs. The platform’s DESIGN, BUILD, TEST, and find out modules enable researchers to effectively collaborate across an organization's development pipeline to style and build experiments, standardize and share data, and learn and preserve project results by embedding them during a machine learning model.

TeselaGen’s DESIGN is an intuitive, user-interface-driven module that permits scientists to style highly complex combinatorial libraries. With this new release, the planning now supports aminoalkanoic acid parts which will be efficiently mapped to DNA. TeselaGen can then automatically generate biology protocols for efficiently synthesizing and assembling the corresponding DNA libraries.

TeselaGen’s DISCOVER now supports AI models which will recommend new peptides and proteins supported by the training of supervised and unsupervised learning models. The platform also supports the modeling of unnatural amino acids and multicriteria optimization of proteins. R&D groups can utilize the TeselaGen OS to hurry the invention process. Datasets are uploaded and arranged within the platform and immediately useful for model building within TeselaGen’s DISCOVER module.

TeselaGen has demonstrated that it can increase the planning and build speed of biological products and reduce the prices related to research & development by an order of magnitude. Current partnering companies are using the new capabilities for designing antibodies and optimizing their binding affinity, titer, specific productivity, immunogenicity, or other phenotypic variables of interest. Researchers also are looking to TeselaGen for rapidly engineering new vaccines - using methods like virus-like particles (VLPs), DNA, and RNA vaccines - opening the door to attacking rapidly mutating RNA and retroviruses like influenza, HCV, HIV, or coronaviruses.

About TeselaGen Biotechnology
TeselaGen Biotechnology has developed the primary artificial intelligence-enabled OS for biotechnology, enabling the event and commercialization of high-performance bioproducts – from pharmaceuticals to food to fabrics – faster and easier than ever. TeselaGen® connects biologists, lab technicians, and bioinformaticians so that they will collaboratively design and build experiments, organize and standardize data then test and continually learn from the info. TeselaGen has been deployed by Fortune 50 companies and emerging innovators in biopharmaceuticals, agriculture, and specialty chemicals. the corporate is privately held and based in San Francisco, California.

Spotlight

The word biotechnology is a cross between the Greek words “bios” (everything to do with life) and “technikos” (involving human knowledge and skills). The OECD (the Organisation of Economic Co-operation and Development) defines biotechnology as “the application of scientific and engineering principles to the processing of materials by biological agents.” More simply, biotechnology is using living organisms to make useful products.


Other News
MEDICAL

Relevate Health Acquires ConneXion360

Relevate Health | April 26, 2022

Relevate Health solidifies its position as the market leader in Healthcare Professional (HCP) omnichannel engagement with the acquisition of Dallas-based ConneXion360. With this acquisition, Relevate Health now provides its omnichannel solutions and agency services to more than 185 brands from 90 pharmaceutical, biotech, and medical device manufacturers, as well as 24 hospital systems. The addition of ConneXion360 expands the Relevate Health suite of HCP engagement marketing solutions for its clients with precision messaging at the point-of-care and point-of-prescribing and Key Account Messaging for 1:1 engagement, complemented by ConneXion360's National Broadcast capabilities and OnDemand platform for "non-personal" engagement. The combination enables Relevate Health's clients to gain access to difficult-to-reach health systems and HCPs via ConneXion360's industry-leading Treatment Perspectives Recruitment Network. These proven solutions will be integrated into Relevate Health's proprietary ElevatedRelevance℠ data platform to cultivate unique and actionable content, market selection, and Key Opinion Leader identification insights for its clients. Relevate Health's comprehensive suite of data-driven HCP Engagement solutions solves the last-mile challenge that many brands face in connecting their creative campaign to target HCP audiences. Relevate Health's digital activation services and marketing solutions plug into existing omnichannel infrastructure and spans the gamut from 1:1 to mass engagement. Bringing ConneXion360's 1:1 engagement, Key Account Messaging, immersive video, and national broadcast capabilities into the Relevate Health suite of products and technology offer new brand-building opportunities for our clients, Quite simply, it means more access to HCPs by the Reps, MSLs, and KAMs, richer opportunities to scale nationally using local data, and deeper omnichannel engagement. For clients seeking a digital-first omnichannel agency, we complement our highly differentiated engagement solutions with class-leading agency services, and digital activation capabilities that help our clients achieve their ambitious growth objectives." Relevate Health CEO Jeff Spanbauer. Relevate Health delivers innovative, integrated HCP omnichannel engagement solutions that are configured to meet clients' specific market challenges. Its unmatched capabilities in "non-personal" promotion, immersive video, peer-to-peer engagement, field rep access, and field rep enablement make Relevate Health the premier marketing partner. Relevate Health delivers precision, segmented, and scalable engagement solutions that overcome the increasing HCP access hurdles. Relevate Health is known for its use of data and machine learning to create locally relevant messages that are scalable, By adding ConneXion360's Treatment Perspectives Recruitment Network and our portfolio of proprietary Treatment Perspectives National & Local HCP Message Engagement Solutions, we can engage target HCPs with more precision, personalization, and relevancy at both national & local levels. Our clients now have access to a single premier partner with a full suite of product-driven, data-based solutions that deliver proven brand growth and extraordinary ROI among previously hard-to-engage HCP audiences." George Griffith, Co-Founder & CEO of ConneXion360. The acquisition of ConneXion360 marks the third transaction by Relevate Health since taking on funding from Denver-based private equity firm Mountaingate Capital in late 2020. Relevate Health's comprehensive system of marketing solutions enables clients of all sizes to deploy a platform that fits their needs. With this acquisition, Relevate Health becomes a single omnichannel partner that addresses the full range of HCP engagement challenges, from 1:1 to National Broadcast, providing field personal as well as brand, digital, and medical leaders with solutions that change HCP's behavior and deliver benchmark beating ROI. Relevate Health, founded in 2007, is an award-winning healthcare marketing agency for pharmaceutical, biotech, and medical device brands, recognized by MM&M, PM360, MedAdNews, and more. ConneXion360 is the leading Health System and HCP Recruitment Network that specializes in creating access for its clients to Health Care Professionals through its proprietary Treatment Perspectives Recruitment Network, National Broadcast platforms, and precision messaging at the point-of-care and the point-of-prescribing.

Read More

MEDICAL

Cardea Bio completes planned launch of CRISPR QC

Cardea Bio | April 06, 2022

Today, Cardea Bio, Inc. - the world's only mass producer of biocompatible semiconductors - announced a significant milestone with the launch of CRISPR QC Inc. as a separate business using Cardea's CRISPR-chip™ technology for a range of quality control services for CRISPR gene editing. This milestone is an important move for Cardea Bio on its mission to realizing real-world applications of their BPU™ (Biosignal Processing Unit) Platform. After recently establishing dedicated lab facilities and office spaces, as well as completing the initial investor funding, CRISPR QC is now ready to offer analysis services for R&D groups in therapeutics, animal breeding, plant biology, and academics in need of advanced insights to their CRISPR efforts. One of the challenges for successful CRISPR gene editing is a lack of understanding and standardization of processes around predicting and optimizing CRISPR assay outcomes. At CRISPR QC, we work with scientists to improve the quality of life for all. That's why we're excited to work with the Chief Scientific Officer of Cardea Bio, Dr. Kiana Aran, who recently received NIH funding to help set some of the US quality control standards for CRISPR therapies, In addition to this, CRISPR QC provides previously unavailable data and insight into the CRISPR editing process, resulting in significant time-savings and first to market application opportunities for our customers, including CRISPR/Cas technology-driven solutions which are commercially available as of now." Ross Bundy, President of CRISPR QC. With CRISPR QC going into business with valuable first-of-a-kind services in the growing CRISPR space, we can now showcase a distinct example of what our BPU Platform can enable our partners to do - products and applications otherwise not possible. That in turn drives growth opportunities and revenue for Cardea Bio, unlocking significant value for both CRISPR QC's and Cardea's stakeholders, I'm anticipating that CRISPR QC will get a number of near-term opportunities to help its customers bring transformative gene-editing insights and solutions to scientists and researchers working on CRISPR therapies, as well as other market changing applications." Michael Heltzen, CEO at Cardea Bio. About CRISPR QC Inc. CRISPR QC is a biotechnology company dedicated to improving the capabilities of scientists and researchers to improve their CRISPR assay designs through technological innovation. Using market-leading solutions, we can identify CRISPR activity in amplicons and genomic DNA and model results of the CRISPR process In vivo vs. In vitro. Our service is available to therapeutic companies and academic researchers to help them accelerate the development of their CRISPR-based therapies and to animal breeding and plant biology scientists who seek to improve the food chain for humankind. About Cardea Bio Cardea Bio is the world's only mass producer of a biocompatible semiconductor, the BPU™ (Biosignal Processing Unit). The BPU is the first and only semiconductor capable of translating real-time streams of multiomics signals into digital information. Through the BPU™ platform, Cardea's long-term vision is to democratize access to the biosignals and insights behind the most advanced technology on our planet: Nature and biology. The Internet of Biology is that way becoming possible. Cardea is headquartered in San Diego and has additional activity in Los Angeles. Cardea is a 100% American developed and built biocompatible semiconductor technology for applications across a variety of sectors including human health, agriculture, molecular diagnostics, biotechnology, environmental monitoring, and animal health.

Read More

MEDICAL

Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center

Anixa | March 31, 2022

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1 trial evaluating its novel chimeric antigen receptor T-cell (CAR-T) therapy in ovarian cancer. The CAR-T approach used for Anixa's therapy is known as chimeric endocrine receptor T-cell (CER-T) since the target of the engineered T-cells is an endocrine receptor. The Phase 1 trial at Moffitt Cancer Center will evaluate the safety and efficacy of Anixa's therapy in patients with ovarian cancer. Anixa holds an exclusive, worldwide license for the technology, which was developed at the Wistar Institute. While CAR-T therapy has shown efficacy in some hematological tumors, reproducing the same results with solid tumors, such as ovarian cancer, has proven challenging. One of the reasons for this difficulty is that effective CAR-T therapy needs a specific antigen to recognize that is only present on target cancer cells in order to avoid negatively affecting healthy cells. The CER-T therapy being evaluated in Anixa's Phase 1 study differs from traditional CAR-T in that it targets the follicle stimulating hormone receptor (FSHR), which research indicates is exclusively expressed on ovarian cells in healthy adult females. We are thrilled to have partnered with world-class scientists at Moffitt Cancer Center to advance our CER-T platform and feel that this partnership provides a critical opportunity to make a significant impact on the treatment of solid tumors, We strongly believe that our unique targeting approach differentiates our CER-T platform from traditional CAR-T approaches and that CER-T has potential to work in solid tumors where other therapies have failed." Dr. Amit Kumar, President, CEO and Chairman of Anixa Biosciences. CAR-T therapies are rapidly becoming an important player in cancer therapy, and our lab has developed a technology that has the potential to target tumors by using an existing biological mechanism that is well understood. If our CER-T approach is successful, it could serve as a model for future targeted CAR-T therapies in other cancer types. The goal in cancer therapy has always been to kill cancer cells with limited damage to healthy tissue, and we look forward to seeing how this CER-T therapy may be able to accomplish that in solid tumors, which have historically proven challenging to eradicate with cell therapy." Jose R. Conejo-Garcia, M.D., Ph.D., Chair of the Department of Immunology at Moffitt Cancer Center and co-inventor of the CER-T technology. About Anixa's CER-T Approach (Follicle Stimulating Hormone Receptor-Mediated CAR-T technology) Anixa's chimeric antigen receptor T-cell (CAR-T) technology approach is an autologous cell therapy comprised of engineered T-cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries. Since the target is a hormone (chimeric endocrine) receptor, and the target-binding domain is derived from its natural ligand, this technology is known as CER-T (chimeric endocrine receptor T-cell) therapy, a new type of CAR-T. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company with a number of programs addressing cancer and infectious disease. Anixa's portfolio of therapeutics includes a cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and, with partner MolGenie GmbH, a COVID-19 program focused on compounds targeting the Mpro enzyme of SARS-CoV-2, which is largely conserved across all recently identified variants like Delta and Omicron. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization

Read More

INDUSTRIAL IMPACT

Cybin Announces Additional Adelia Milestone Achievement

Cybin Inc. | January 28, 2022

Cybin Inc. a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. a wholly-controlled subsidiary of Cybin, has achieved the milestones identified as Y1, Q4 (iv), Y1, Q4 (v) and Y2, Q1 (vi) as contemplated by the terms of a contribution agreement dated December 4, 2020 among Cybin, Cybin Corp., Cybin US Holdings Inc. a wholly-controlled subsidiary of Cybin, and all of the previous shareholders of Adelia. Pursuant to the terms of the Transaction Agreement, Class B common shares in the capital of the Acquiror shall be issued to the Adelia Shareholders, in satisfaction of the $551,171.99 due to them on meeting a portion of the relevant milestones, at an effective issue price determined in accordance with the Transaction Agreement and applicable securities law. The Class B Shares issued by the Acquiror to the Adelia Shareholders are exchangeable for common shares in the capital of Cybin on a 10 Cybin Shares for 1 Class B Share basis, at the option of the holder thereof, subject to customary adjustments. No Class B Shares were exchangeable prior to December 14, 2021, and not more than: (i) 33 1/3% of the Class B Shares will be exchangeable prior to December 14, 2022; (ii) 66 2/3% of the Class B Shares will be exchangeable prior to December 14, 2023; and (iii) thereafter, 100% of the Class B Shares will be exchangeable. About Cybin Cybin is a leading ethical biotechnology company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics™ by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. About Adelia Adelia is a wholly-controlled subsidiary of the Company, that aims to develop medicinal psychedelics with improved dosing efficacy and therapeutic indices to address unmet medical needs. Adelia’s primary focus is on the development of treatment regimens consisting of proprietary psychedelic molecules and related clinical protocols. This proprietary development strategy is based on chemical modifications to the known and well understood tryptamine derivatives that significantly modify their pharmacokinetic properties without changing their therapeutic potential. These proprietary approaches seek to minimize inter-patient variability by better controlling drug metabolism without loss of efficacy that together have been shown to produce more predictable and favorable patient outcomes.

Read More

Spotlight

The word biotechnology is a cross between the Greek words “bios” (everything to do with life) and “technikos” (involving human knowledge and skills). The OECD (the Organisation of Economic Co-operation and Development) defines biotechnology as “the application of scientific and engineering principles to the processing of materials by biological agents.” More simply, biotechnology is using living organisms to make useful products.

Resources